D I G I T A L D I A G N O S T I C S
Dr Alan D Roth , CEO of Oxford Drug Design methods , the process of identifying a target and then designing a molecule against using conventional means was significantly slower and less accurate .
Our platform Synth AI , for example , helps preclinical drug discoverers find innovative molecules fulfilling three key metrics : they possess the required biological activity against disease , can be made using known chemical processes , and can be produced at scale .
This approach means that treatments are developed with greater accuracy and are therefore much more likely to achieve validation at every stage of preclinical and clinical trials . Drugs coming to market after such an accelerated process are more cost-effective to produce , making the space highly attractive for investors while improving outcomes for physicians and patients .
Overall , these new AI-enabled drugs stand to be of superior efficacy and safety when replacing older drugs with limitations in both criteria . AI truly has the potential to revolutionise global medical and specifically therapeutic care .
The future of AI in the clinic
Looking to the future of AI , one of the key features of our approach is its increasing flexibility .
64 www . intelligenthealth . tech